Infection site concentrations: Their therapeutic importance and the macrolide and macrolide-like class of antibiotics

Pharmacotherapy

Volumn 25, Issue 12 II, 2005, Pages

  Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Infection site concentration; Macrolide; Population modeling

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; ERYTHROMYCIN; GATIFLOXACIN; KETOLIDE; MACROLIDE; RADIOISOTOPE; RIFAMPICIN; TELITHROMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL GROWTH; BACTERIAL PNEUMONIA; CASE CONTROL STUDY; COLONY FORMING UNIT; CONFERENCE PAPER; DRUG PENETRATION; DRUG TISSUE LEVEL; ERADICATION THERAPY; EXPERIMENTAL MOUSE; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISOTOPE LABELING; KAPLAN MEIER METHOD; LUNG FLUID; MATHEMATICAL MODEL; MAXILLA SINUSITIS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OTITIS MEDIA; PHAGOCYTOSIS; PHARMACODYNAMICS; POPULATION MODEL; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; VOLUNTEER;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; CHEMOTAXIS, LEUKOCYTE; HUMANS; LEUKOCYTES; MACROLIDES; MICE; MICROBIAL SENSITIVITY TESTS; RESPIRATORY MUCOSA; TISSUE DISTRIBUTION;

EID: 29044441066     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.12part2.150S     Document Type: Conference Paper

References (32)

1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
2. Drusano GL. Antimicrobial pharmacodynamics: interactions of 'bug and drug.' Natl Rev Microbiol 2004;2:289-300.
3. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
4. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279:125-9.
5. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. The relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004;189:1590-7.
6. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793-7.
7. Bosnar M, Kelneric Z, Munic V, Erakovic V, Parnham MJ. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 2005;49:2372-7.
8. Frank MO, Sullivan GW, Carper HT, Mandell GL. In vitro demonstration of transport and delivery of antibiotics by polymorphonuclear leukocytes. Antimicrob Agents Chemother 1992;36:2584-8.
9. Mandell GL, Coleman E. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2001;45:1794-8.
10. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
11. Retsema JA, Bergeron JM, Girard D, Milisen WB, Girard AE. Preferential concentration of azithromycin in an infected mouse thigh model. J Antimicrob Chemother 1993;31(suppl E):5-16.
12. Karma P, Pukander J, Penttila M. Azithromycin concentrations in sinus fluid and mucosa after oral administration. Eur J Clin Microbiol Infect Dis 1991;10:856-9.
13. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003;47:2450-7.
14. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997;41:1399-402.
15. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996;40:2375-9.
16. Khair OA, Andrews JM, Honeybourne D, Jevons G, Vacheron F, Wise R. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001;47:837-40.
17. Ambrose PG, Anon JB, Owen JS, et al. Use of pharmacodynamic endpoints in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin Infect Dis 2004;38:1513-20.
18. Fleishaker JC, McNamara PJ. Performance of a diffusional clearance model for beta-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics. Antimicrob Agents Chemother 1985;28:369-74.
19. Gudnason T, Gudbrandsson F, Barsanti F, Kristinsson KG. Penetration of ceftriaxone into the middle ear fluid of children. Pediatr Infect Dis J 1998;17:258-60.
20. Green SM, Rothrock SG. Single-dose intramuscular ceftriaxone for acute otitis media in children. Pediatrics 1993;91:23-30.
21. Barnett ED, Teele DW, Klein JO, Cabral HJ, Kharasch SJ. Comparison of ceftriaxone and trimethoprim-sulfamethoxazole for acute otitis media. Greater Boston otitis media study group. Pediatrics 1997;99:23-8.
22. Cohen R, Navel M, Grunberg J, et al. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: clinical efficacy and change in nasopharyngeal flora. Pediatr Infect Dis J 1999;18:403-9.
23. Wang CY, Lu CY, Hsieh YC, Lee CY, Huang LM. Intramuscular ceftriaxone in comparison with oral amoxicillin-clavulanate for the treatment of acute otitis media in infants and children. J Microbiol Immunol Infect 2004;37:57-62.
24. Blumer JL, Reed MD, Kaplan EL, Drusano GL. Explaining the poor bacteriological eradication rate of single-dose ceftriaxone in Group A streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling. Pediatrics 2005;116:927-32.
25. Leary RJ, Schumitzky A, van Guilder M. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings, 14th IEEE symposium on computer-based medical systems. Bethesda, MD: IEEE Computer Society, 2001:389-94.
26. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-64.
27. Maglio D, Capitano B, Banavicius MA, Geng Q, Nightingale CH, Nicolau DP. Differential efficacy of clarithromycin in lung vs thigh infection models. Chemotherapy 2004;50:63-6.
28. Novelli A, Fallani S, Cassetta MI, Arrigucci S, Mazzel T. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. J Chemother 2002;14:584-90.
29. Tessier PR, Kim MK, Zhou W, et al. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002;46:1425-34.
30. Tessier PR, Mattoes HM, Dandekar PK, Nightingale CH, Nicolau DP. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 2005;49:188-94.
31. Dandekar PK, Williams P, Tessier PR, Farrell DJ, Nightingale CH, Nicolau DP. Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model. Int J Antimicrob Agents 2005;25:530-4.
32. Zhanel GG, Johanson C, Laing N, Hisananga T, Wierzbowski A, Hoban DJ. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary. Antimicrob Agents Chemother 2005;49:1943-8.